Search for: [Abstract = "ecorded for DAS28\-CRP \(44.7%\), followed by DAS28\-ESR \(33.3%\), SDAI \(21.9%\), CDAI \(19.3%\), cDAPSA \(14.9 %\) and DAPSA \(13.2%\) Only 2.6% of patients achieved remission defined according to the Boolean criteria, 25.4% achieved MDA and 4.4% VLDA. After 5 years, the proportion of patients achieving remission increased significantly for DAS28\-CRP \(\+11.1%, p = 0.033\), DAS28\-ESR \(\+21.2%, p < 0.001\), CDAI \(\+9.7%, p = 0.034\) and cDAPSA \(\+7.6%, p = 0.028\). Non\-significant increases were observed for SDAI, DAPSA, Boolean remission and MDA\/VLDA. Both at baseline and after 5\-year follow\-up, more men than women were treated with bDMARDs and these differences were statistically significant \(baseline\: p = 0.048, followup\: p = 0.008\). Women scored higher on generalized pain, joint pain and fatigue, had higher numbers of tender joints and enthesitis scores, higher DAPSA, cDAPSA, SDAI, CDAI, DAS28\-ESR, DAS28\-CRP and significantly higher number of comorbidities both at baseline and at follow\-up. Conclusions 1. In RA patients treated with RTX in monotherapy \(without concomitant use of csDMARDs\), no differences in neither drug effectiveness nor drug survival were observed, comparing to concomitant users of csDMARDs. Previous use of bDMARDs other than RTX did not affect drug effectiveness and drug survival. A significant response to RTX treatment was observed mainly in the second year"]
